BC exhibits significant heterogeneity, both among different patients and within tumors from the same individual, primarily characterized by variations in hormone receptor status, HER2 expression, mutational landscape, and intratumoral heterogeneity 143,144. This evidence concerns the gene ERBB2 and breast cancer.